Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Role of Immunotherapy for Renal Cell Cancer in 2011

(2017) Saby George et al.   Journal of the National Comprehensive Cancer Network

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

(2014) C. Lebbe et al.   ANNALS OF ONCOLOGY

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

(2014) J J Ko et al.   BRITISH JOURNAL OF CANCER

Priming of a Novel Subset of CD28+ Rapidly Expanding High-Avidity Effector Memory CTL by Post Maturation Electroporation-CD40L Dendritic Cells Is IL-12 Dependent

(2014) M. A. DeBenedette et al.   JOURNAL OF IMMUNOLOGY

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

(2013) R J Motzer et al.   BRITISH JOURNAL OF CANCER

Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial

(2013) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Dendritic Cells in the Cancer Microenvironment

(2013) Yang Ma et al.   Journal of Cancer

Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response

(2013) Jacoba G Slagter-Jäger et al.   Molecular Therapy-Nucleic Acids

Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST

(2012) Mizuki Nishino et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Targeted therapeutic strategies for the management of renal cell carcinoma

(2012) Eric A. Singer et al.   CURRENT OPINION IN ONCOLOGY

The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs

(2012) Saroj Niraula et al.   JOURNAL OF CLINICAL ONCOLOGY

Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma

(2012) Laurence Albiges et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

(2012) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials

(2011) Chris Coppin et al.   BJU INTERNATIONAL

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies

(2011) M E Gore et al.   BRITISH JOURNAL OF CANCER

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

(2011) Ana M. Molina et al.   CANCER

Autocrine IL-2 is required for secondary population expansion of CD8+ memory T cells

(2011) Sonia Feau et al.   NATURE IMMUNOLOGY

Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities

(2011) C. Kollmannsberger et al.   ONCOLOGIST

Potency of Mature CD40L RNA Electroporated Dendritic Cells Correlates With IL-12 Secretion by Tracking Multifunctional CD8+/CD28+ Cytotoxic T-cell Responses In Vitro

(2010) Mark A. DeBenedette et al.   JOURNAL OF IMMUNOTHERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma

(2009) Premal H. Patel et al.   Clinical Genitourinary Cancer

Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma

(2009) Darren R. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

(2009) Daniel Y.C. Heng et al.   JOURNAL OF CLINICAL ONCOLOGY

In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer

(2009) Franck Pagès et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy

(2009) Michael B. Atkins   MEDICAL ONCOLOGY

Reversal of Myeloid Cell-Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma

(2008) S. Kusmartsev et al.   CLINICAL CANCER RESEARCH

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH

Cytokine Maturation Followed by CD40L mRNA Electroporation Results in a Clinically Relevant Dendritic Cell Product Capable of Inducing a Potent Proinflammatory CTL Response

(2008) David M. Calderhead et al.   JOURNAL OF IMMUNOTHERAPY

Multiplex RT-PCR Amplification of HIV Genes to Create a Completely Autologous DC-Based Immunotherapy for the Treatment of HIV Infection

(2008) Irina Tcherepanova et al.   PLoS One

Memory T cells in cancer immunotherapy: which CD8+T-cell population provides the best protection against tumours?

(2008) R. Perret et al.   TISSUE ANTIGENS